This article outlines the strengths and weaknesses of drug-drug comparative effectiveness research (CER), with a specific focus on heart failure research, to characterize the optimal use of and approaches to CER. Although there have been important therapeutic advances in heart failure over the past several decades, CER provides great opportunities for guiding researchers and clinicians in improving management of this important disease characterized by excess morbidity, mortality, and costs.